VANCOUVER, British Columbia, May 17, 2021 (GLOBE NEWSWIRE) — Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE:DRUG) (OTCQB:BMBIF), a biotechnology company focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain, today announced that its shares will commence trading on the OTCQB® Venture Market (the “OTCQB”) on May 17, 2021, under…
VANCOUVER, British Columbia, May 11, 2021 (GLOBE NEWSWIRE) — Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE:DRUG), a biotechnology company focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain, today announced that Ian McDonald, Chief Executive Officer, and Dr. Gideon Shapiro Ph.D, Vice President of Discovery, will be presenting at…
Vancouver, British Columbia, May 4, 2021 – Bright Minds Biosciences Inc. (CSE:DRUG) (“Bright Minds” or the “Company”) announces that it has granted an aggregate of 240,000 stock options (the “Options”) to consultants of the Company to purchase 240,000 common shares (the “Shares”)in the capital of the Company pursuant to the Company’s share option plan. The…
VANCOUVER, British Columbia, April 27, 2021 (GLOBE NEWSWIRE) — Bright Minds Biosciences (“Bright Minds” or the “Company”), a biotechnology company focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain, today announced two additions to its leadership team and one new scientific advisor as follows: Jianmin Duan, PhD, Vice President, Pharmacology, will lead…
VANCOUVER, BC – April 23, 2021 – Bright Minds Biosciences Inc. (CSE: DRUG) (the “Company”), a biotechnology company focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy and pain, is pleased to announce that, pursuant to the exercise of its option under the Option Agreement (as herein defined), it has entered into an exclusive…
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, British Columbia, March 17, 2021 (GLOBE NEWSWIRE) — Bright Minds Biosciences Inc. (CSE:DRUG) (“Bright Minds” or the “Company”) is pleased to announce that it has…
— BMB compound significantly reduced fentanyl intake in an animal model of opioid abuse — — Potential to reduce continued opioid use in humans, a key treatment goal for opioid use disorder — — A brief virtual presentation discussing the findings is scheduled for Monday, March 15th at 11am ET — VANCOUVER, British…
VANCOUVER, British Columbia, March 10, 2021 (GLOBE NEWSWIRE) — Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE:DRUG), a biotechnology company focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain, today announced that Ian McDonald, Chief Executive Officer, will be presenting at the Stifel GMP Healthcare Conference – Healthcare Psychedelics: Addressing…
— Model is predictive for human efficacy for binge eating — — BMB compound reduced binge eating in rats with a clear dose range for efficacy — — A virtual presentation discussing the findings is tentatively scheduled for Wednesday, March 10th at 11:00AM EST — VANCOUVER, British Columbia, March 03, 2021 (GLOBE NEWSWIRE)…
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, British Columbia, Feb. 23, 2021 (GLOBE NEWSWIRE) — Bright Minds Biosciences Inc. (CSE:DRUG) (“Bright Minds” or the “Company”) announces the pricing of its previously announced…
×
"*" indicates required fields